Importer of Controlled Substances Application: Fresenius Kabi USA, LLC, 41053 [2017-18312]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 166 / Tuesday, August 29, 2017 / Notices
(approximately $500); for a total of
$138,188. We have not identified any
other non-hour cost burdens associated
with this collection of information.
Abstract: This notice concerns the
paperwork requirements of 30 CFR 250,
Subpart M, Unitization, and related
documents. The BSEE must approve any
lessee’s proposal to enter an agreement
to unitize operations under two or more
leases and for modifications when
warranted. We use the information to
ensure that operations under the
proposed unit agreement will result in
preventing waste, conserving natural
resources, and protecting correlative
rights including the government’s
interests.
The authorities for this action are the
Outer Continental Shelf Lands Act
(OCSLA, 43 U.S.C. 1334), the Federal
Oil and Gas Royalty Management Act
(FOGRMA, 30 U.S.C. 1751), the
Independent Offices Appropriations Act
(IOAA, 31 U.S.C. 9701), and the
Paperwork Reduction Act of 1995 (44
U.S.C. 3501, et seq.).
Dated: July 21, 2017.
Doug Morris,
Chief, Office of Offshore Regulatory Programs.
[FR Doc. 2017–18264 Filed 8–28–17; 8:45 am]
BILLING CODE 4310–VH–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 731–TA–891 (Third
Review)]
Foundry Coke From China: Notice of
Commission Determination To
Conduct a Full Five-Year Review
Authority: This review is being conducted
under authority of title VII of the Tariff Act
of 1930; this notice is published pursuant to
section 207.62 of the Commission’s rules.
United States International
Trade Commission.
ACTION: Notice.
AGENCY:
SUMMARY: The Commission hereby gives
notice that it will proceed with a full
review pursuant to the Tariff Act of
1930 to determine whether revocation of
the antidumping duty order on foundry
coke from China would be likely to lead
to continuation or recurrence of material
injury within a reasonably foreseeable
time. A schedule for the review will be
established and announced at a later
date.
sradovich on DSK3GMQ082PROD with NOTICES
DATES:
August 4, 2017.
Abu
B. Kanu (202–205–2597), Office of
Investigations, U.S. International Trade
Commission, 500 E Street SW.,
Washington, DC 20436. Hearingimpaired persons can obtain
information on this matter by contacting
the Commission’s TDD terminal on 202–
FOR FURTHER INFORMATION CONTACT:
VerDate Sep<11>2014
18:45 Aug 28, 2017
Jkt 241001
205–1810. Persons with mobility
impairments who will need special
assistance in gaining access to the
Commission should contact the Office
of the Secretary at 202–205–2000.
General information concerning the
Commission may also be obtained by
accessing its internet server (https://
www.usitc.gov). The public record for
this review may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov.
For further information concerning
the conduct of this review and rules of
general application, consult the
Commission’s Rules of Practice and
Procedure, part 201, subparts A through
E (19 CFR part 201), and part 207,
subparts A, D, E, and F (19 CFR part
207).
SUPPLEMENTARY INFORMATION: On August
4, 2017, the Commission determined
that it would proceed to a full review in
the subject five-year review pursuant to
section 751(c) of the Tariff Act of 1930
(19 U.S.C. 1675(c)). In response to the
Commission’s notice of institution (82
FR 20381, May 1, 2017), the
Commission found that the domestic
interested party group response was
adequate and the respondent interested
party group response was inadequate.
The Commission also found that other
circumstances warranted conducting a
full review.1 A record of the
Commissioners’ votes, the
Commission’s statement on adequacy,
and any individual Commissioner’s
statements will be available from the
Office of the Secretary and at the
Commission’s Web site.
By order of the Commission.
Issued: August 23, 2017.
Katherine M. Hiner,
Supervisory Attorney.
[FR Doc. 2017–18227 Filed 8–28–17; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Fresenius Kabi USA, LLC
ACTION:
Notice of application.
1 Vice
Chairman Johanson and Commissioner
Broadbent voted to conduct a full review of the
order. Chairman Schmidtlein and Commissioner
Williamson voted to conduct an expedited review
of the order.
PO 00000
Frm 00072
Fmt 4703
Sfmt 9990
41053
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.34(a) on
or before September 28, 2017. Such
persons may also file a written request
for a hearing on the application
pursuant to 21 CFR 1301.43 on or before
September 28, 2017.
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
ADDRESSES:
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on June 5,
2017, Fresenius Kabi USA, LLC, 3159
Staley Road, Grand Island, New York
14072 applied to be registered as an
importer of remifentanil (9739), a basic
class of controlled substance listed in
schedule II.
The company plans to import the
listed controlled substance for product
development and preparation of
stability batches.
SUPPLEMENTARY INFORMATION:
Dated: August 21, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017–18312 Filed 8–28–17; 8:45 am]
BILLING CODE 4410–09–P
E:\FR\FM\29AUN1.SGM
29AUN1
]]>Agencies
[Federal Register Volume 82, Number 166 (Tuesday, August 29, 2017)]
[Notices]
[Page 41053]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-18312]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Fresenius Kabi
USA, LLC
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration in accordance with 21 CFR
1301.34(a) on or before September 28, 2017. Such persons may also file
a written request for a hearing on the application pursuant to 21 CFR
1301.43 on or before September 28, 2017.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
request for hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on June
5, 2017, Fresenius Kabi USA, LLC, 3159 Staley Road, Grand Island, New
York 14072 applied to be registered as an importer of remifentanil
(9739), a basic class of controlled substance listed in schedule II.
The company plans to import the listed controlled substance for
product development and preparation of stability batches.
Dated: August 21, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017-18312 Filed 8-28-17; 8:45 am]
BILLING CODE 4410-09-P
